Intravenous immunoglobulin (IVIg) is a solution of human IgG, salt, sugars and solvents used to treat a multitude of diseases. Although IVIg has been known to treat many diseases safely and successfully, there are relatively few supporting randomized controlled trials. In part two of this review, we assess the clinical indications of IVIg in dermatological disorders and the outcomes of its use.
Introduction
In the first part of this review, we addressed the biological mechanisms of intravenous immunoglobulins (IVIg) and the pragmatics of delivery.
1 In this part, we explore the most pertinent evidence relating to the use of IVIgs for various dermatological indications.
Clinical indications Dermatomyositis
Dermatomyositis is a rare inflammatory disorder with cutaneous and extracutaneous manifestations. Indications for the use of IVIg in cutaneous dermatomyositis include patients with an expert diagnosis of the disease, in conjunction with corticosteroid resistance with uncontrolled active disease and hospitalization secondary to bulbar or respiratory involvement despite conventional corticosteroid or immunosuppressant therapy. 2 The Department of Health (DoH) guidelines for dosing advise: "2 doses of IVIg (2 g/kg given over several days) 6 weeks apart; restarted at relapse and repeated using the 'time to relapse' as the interval between courses". By contrast, recently published European guidelines advise 4-weekly intervals initially; this can be increased to 6-weekly in the event of lack of clinical response. 3 A 4-year long-term follow-up study of 42 patients found the muscular remission rate for IVIg to be significantly higher (P = 0.007) than the conventional immunosuppressant cohort with less cutaneous and muscular involvement. 5 However, general conclusions are difficult to draw owing to the small sample size and the retrospective analysis of patient records. Of note, studies to date have primarily commented on musculoskeletal improvement post-IVIg treatment, not cutaneous outcomes.
Kawasaki disease
Kawasaki disease (KD) is a medium-vessel vasculitis that most commonly presents in children. IVIg is indicated in all children presenting with KD, primarily to prevent coronary artery abnormalities. 3 The largest retrospective study of 1073 patients concluded that IVIg improves the initial severity of coronary lesions as measured by coronary artery aneurysm regression, but it does not provide protection against long-term development of coronary artery aneurysms. 6 A retrospective review (n = 216) of IVIg as an adjunct to dexamethasone vs. IVIg therapy alone found combined therapy to be have a favourable profile, with less fever occurring, fewer IVIg courses required and shorter length of hospital stay. 7 The dose of IVIg given in KD 8 or divided into an infusion over 2-5 days. 3 A meta-analysis of randomized controlled trials (RCTs) of IVIg vs. placebo in children with KD demonstrated a relative risk reduction of 0.74 for new coronary artery abnormalities 30 days after IVIg treatment, and suggested that children with KD should be treated with a single dose of IVIg within 10 days of symptom onset. 9 The DoH guidelines advise that outcome is calculated by resolution of fever and that IVIg is to be given in conjunction with aspirin, with a second dose advised if fever does not resolve or if there is a relapse within 2 days. 2 Athough the guidelines are clear regarding IVIg use in KD in children, IVIgs are not licensed for adults, who are less frequently affected by KD.
Graft-versus-host disease
Graft-versus-host disease (GVHD) results when nonautologous tissue (such as a bone marrow transplant) results in a potentially fatal attack by the recipient immune system. First-line treatment is systemic corticosteroids. A double-blind RCT of 618 patients investigated whether varying doses of IVIg affected GVHD outcome following allogenic marrow transplantation. The study started patients on 90 days of weekly IVIg, followed by monthly IVIg until 1 year post-transplant, using doses of 0.1, 0.25 and 0.5 g/kg. The outcome of GVHD was not dose-dependent, but the frequency of adverse effects (AEs) increased with higher doses of IVIg, suggesting that lower doses should be trialled initially for costeffectiveness. 10 The updated 2011 DoH guidelines no longer include IVIg as a suggested treatment option for GVHD, owing to the poor underlying evidence base comparing IVIg with less expensive and more accessible treatment options. 2 
Pemphigus vulgaris
An RCT of 51 patients with corticosteroid-resistant pemphigus vulgaris (PV) found that higher doses of IVIg (0.4 vs. 0.3 g/kg per day or no IVIg) resulted in significantly reduced disease activity and autoantibody titres 11 (Table 1 ). This study concluded that a single 6-day treatment course of IVIg is safe and effective in corticosteroid-recalcitrant PV. Of note, this paper defined corticosteroid resistance as requiring ≥ 20 mg/day prednisolone.
A 2015 study evaluated the outcome of high-dose IVIg (2 g/kg per cycle) divided over 5 days (n = 10) in patients with PV who had relapsed on corticosteroid tapering or had experienced AEs from steroid-sparing agents. The Pemphigus Disease Area Index was used to evaluate IVIg efficacy, and at the 12-month follow-up, this score had significantly reduced by 98%, in conjunction with a significant corticosteroid dose reduction of 90% (P = 0.002). Mean initial prednisolone dose was 201.6 AE 17 mg/day (significantly higher than the 'defined corticosteroid resistance' of the previously mentioned study), 11 which suggests that IVIg could be beneficial in carefully selected patients. 12 
Cutaneous lupus
IVIg is not currently licensed for cutaneous lupus, but it is often considered as an adjunct alongside immunosuppressants. One study reviewed the use of IVIg in 16 patients with cutaneous lupus (including discoid lupus erythematosus, subacute cutaneous lupus erythematosus, lupus panniculitis and lupus erythematosus tumidus) that was recalcitrant to first-line therapies such as corticosteroids, hydroxychloroquine, mepacrine, methotrexate, mycophenolate mofetil, cyclophosphamide and azathioprine. 13 IVIg at 500 mg/kg per day was given for 4 days, with up to a total of 2 g/kg per month for 3 months, resulting ub a reported improvement of 30% in the Cutaneous Lupus Erythematosus Disease Area and Severity Index, with only three patients suffering a temporary relapse posttreatment and with no serious AEs noted. 14 A more recent meta-analysis of 17 studies (with at least 8 patients per cohort) suggested that treatment with high-dose IVIg has lower mortality than treatment with low-dose IVIg (18.9% vs. 50%), but multivariate logistic regression failed to correlate IVIg with mortality reduction. The authors also highlighted that the majority of studies were not RCTs, making it more difficult to draw definitive inferences. 15 Routine use of IVIg in SJS/TEN has not been advocated in the recent British Association of Dermatologists TEN guidelines, 15 given the paucity of evidence in reduction of mortality rate compared with supportive care alone. 16, 17 Interestingly, however, IVIg can be considered in confirmed early cases of TEN in a single cycle (dose of at least 3 mg/kg) over 3-5 days in the recently published European IVIg guidelines. 3 Worldwide, the management of TEN and use of IVIg varies widely.
Miscellaneous
Small studies consisting mainly of case reports support the use of IVIg use in scleroderma, 16, 17 scleromyxoedema, 18, 19 bullous pemphigoid, 20 pyoderma gangrenosum, 21 atopic dermatitis, 22 chronic urticaria 24, 25 and pretibial myxoedema, 24, 25 all of which are detailed in Table 1 .
Conclusion
Although there are many case studies of IVIg use in dermatology, there have been few RCTs, most of which have been poorly powered. The cost, global availability and AEs of IVIg treatment may ultimately limit this treatment to diseases that prove refractory to conventional treatments or that pose a serious risk of mortality or profound morbidity, and this is reflected in the strict selection criteria found within the IVIg guidelines.
Learning points
• IVIg is a safe treatment option for a multitude of autoimmune diseases.
• More recently, its utility has been expanded to off-label uses.
• Cost, global availability and AEs of treatment may ultimately limit this treatment to diseases that prove refractory to conventional treatments.
• This review enables clinicians to evaluate the latest evidence using up-to-date guidelines in order to elect when best to use IVIg as a treatment option.
• It provides the recent evidence on the use of IVIg based on both the recent national British Association of Dermatologists guidelines and the European IVIg guidelines.
• It also provides knowledge to ensure the best health outcomes are reached when deciding whether IVIg is an appropriate management option. 
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CPD questions Learning objective
To demonstrate up-to-date knowledge in the clinical indications and outcomes of IVIG
